CSPIA
CRL icon

Cary Street Partners Investment Advisory’s Charles River Laboratories CRL Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6
Closed -$1.18K – 861
2023
Q3 		$1.18K Buy
+6
New +$1.23K ﹤0.01% 1721

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Cary Street Partners Investment Advisory's CRL Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Charles River Laboratories (CRL) in Q4 2023, closing a stake of 6 shares — an estimated $1.18K sold.

Cary Street Partners Investment Advisory first reported a position in CRL in Q3 2023 and held it in 1 quarter. The position peaked at $1.18K in Q3 2023. 634 funds tracked by Wall St. Rank hold CRL as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Charles River Laboratories position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 6 Charles River Laboratories shares in Q4 2023, an estimated $1.18K.
  • Cary Street Partners Investment Advisory first reported a position in Charles River Laboratories in Q3 2023 and held it in 1 quarter.
  • Cary Street Partners Investment Advisory's Charles River Laboratories position peaked at $1.18K in Q3 2023.
  • 634 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.